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his document has been developed by the American Col-
ege of Cardiology Foundation (ACCF) Task Force on
linical Expert Consensus Documents, the American Col-
ege of Gastroenterology (ACG), and the American Heart
ssociation (AHA). Expert consensus documents (ECDs)
re intended to inform practitioners, payers, and other
nterested parties of the opinion of the ACCF and docu-
ent cosponsors concerning evolving areas of clinical prac-
ice and/or technologies that are widely available or new to
he practice community. Topics chosen for coverage by
CDs are so designed because the evidence base, the
xperience with technology, and/or the clinical practice are
ot considered sufficiently well developed to be evaluated by
he formal American College of Cardiology/Americaneart Association (ACC/AHA) practice guidelines pro- tess. Often the topic is the subject of ongoing investigation.
hus, the reader should view ECDs as the best attempt of
he ACCF and other cosponsors to inform and guide
linical practice in areas where rigorous evidence may not be
vailable or the evidence to date is not widely accepted.
hen feasible, ECDs include indications or contraindica-
ions. Topics covered by ECDs may be addressed subse-
uently by the ACC/AHA Practice Guidelines Committee
s new evidence evolves and is evaluated.
The Task Force on ECDs makes every effort to avoid any
ctual or potential conflicts of interest that might arise as a
esult of an outside relationship or personal interest of a
ember of the writing panel. Specifically, all members of
he writing panel are asked to provide disclosure statements
f all such relationships that might be perceived as real or
otential conflicts of interest to inform the writing effort.
hese statements are reviewed by the parent task force,
eported orally to all members of the writing panel at the
rst meeting, and updated as changes occur. The relation-
hips with industry information for writing committee
embers and peer reviewers are listed in Appendixes 1 and
, respectively.
Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on
Clinical Expert Consensus Documents
ntroduction
he use of antiplatelet therapies continues to increase as a
esult of accumulation of evidence of benefits in both
rimary and secondary treatment strategies for cardiovascu-
ar disease (1,2). These antiplatelet agents, however, have
ecognizable risks—in particular, gastrointestinal (GI) com-
lications such as ulceration and related bleeding. These
isks may be further compounded by the ancillary use of
ther adjunctive medications, such as nonsteroidal anti-
nflammatory drugs (NSAIDs), corticosteroids, and antico-
gulants. Given the high prevalence of antiplatelet therapy
n clinical practice, coupled with an increased emphasis on
heir extended use, especially after implantation of a drug-
luting stent (3,4), it is imperative that physicians know the
otential benefits and the associated risks of antiplatelet
herapy for primary or secondary prevention of cardiac
schemic events when combined with NSAID agents. Only
ith this understanding can physicians appropriately and
ully evaluate the risk profile for each patient and either
hange medications or initiate prophylactic therapy in an
ttempt to reduce GI complications. This document pro-
ides consensus recommendations from the ACCF, the
HA, and the ACG on the combined use of antiplatelets
nd NSAID agents.
Many NSAIDs, both selective and nonselective, increase the
isk of cardiovascular and cerebrovascular events. This issue
as addressed in a scientific statement from the AHA (5). Inerms of cardiovascular, GI, renal, and hypertension-inducing
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especially the cyclo-oxygenase-2 [COX-2] inhibitors), which
hould also be understood and considered in managing patients
n need of these agents (6). The AHA statement introduces a
tepped-care approach for selection of drugs to manage mus-
uloskeletal discomfort in patients with known cardiovascular
isease or risk factors for ischemic heart disease, based on the
isk/benefit balance from a cardiovascular perspective. A fur-
her discussion of the cardiovascular and cerebrovascular risks
f NSAIDs is beyond the scope of this report but may be
ound in several reviews (5,7).
revalence of Use—NSAIDs/Aspirin (ASA)
he use of NSAIDs, including ASA, is common in the
reatment of pain, inflammation, and fever. Additionally,
ow-dose ASA is used routinely in primary and secondary
rophylaxis of cardiovascular and cerebrovascular events.
hese agents, both through prescription and over-the-
ounter (OTC) use, are the most widely used class of
edications in the United States (8). Not surprisingly,
SAID use increases among the elderly. In a survey of
eople 65 years of age and older, 70% used NSAIDs at least
nce weekly, and 34% used them at least daily. The prevalence
f at least weekly ASA usage was 60% (9). More than 111
illion NSAID prescriptions were written in 2004 (10).
Recognizably, much of this usage comes from noncardiac
ndications, such as arthritis and related musculoskeletal
omplaints, in particular. In 1990, the estimated prevalence
f self-reported arthritis in the United States was 37.9
illion cases, or 15% of the population. By 2020, it is
rojected that 59.4 million will be affected—a 57% increase
rom 1990 (11). As the incidence of arthritis complaints
ncreases, the use of prescription and OTC NSAIDs is also
xpected to increase.
echanisms of GI Injury—NSAIDs
complete discussion of the pathogenesis of ASA- and
SAID-associated injury is beyond the scope of this article;
owever, ASA, like all NSAIDs, injures the gut by causing
opical injury to the mucosa and systemic effects induced by
rostaglandin depletion. Tissue prostaglandins are produced
ia 2 pathways: a COX-1 and a COX-2 pathway. The
OX-1 pathway is the predominant constitutive pathway;
rostaglandins derived from this enzyme mediate many
ffects, most notably facilitating gastroduodenal cytoprotec-
ion, renal perfusion, and platelet activity. The COX-2
athway, in contrast, is inducible by inflammatory stimuli
nd mediates effects through prostaglandins, which result in
nflammation, pain, and fever.
Inhibition of the COX-1 pathway blocks production of
rostaglandins that play an important protective role in the
tomach by increasing mucosal blood flow and stimulating
he synthesis and secretion of mucus and bicarbonate, as gell as promoting epithelial proliferation. Accordingly, the
nhibition of these prostaglandins impairs these protective
actors, resulting in a gastric environment that is more
usceptible to topical attack by endogenous factors, such as
cid, pepsin, and bile salts (12). A major consequence of
rostaglandin depletion is to create an environment that is
onducive to peptic ulcer formation and serious GI compli-
ations. Since prostaglandins are essential to both the
aintenance of intact GI defenses and normal platelet
unction, nonselective NSAIDs such as ASA promote ulcer
ormation as well as bleeding (13).
Because COX-2 is the primary intended target for
nti-inflammatory drug therapy, agents that selectively
lock COX-2, while having little to no effect on COX-1,
hould result in effective pain relief with reduced GI
oxicity. This concept, called the “COX-2 hypothesis,” has
een challenged by data from animal studies, which indi-
ated that both COX-1 and COX-2 must be inhibited for
astric ulceration to occur. Interestingly, while the selective
nhibition of either COX-1 or COX-2 alone failed to cause
astric damage, inhibition of both COX isoforms produced
astric ulceration (14). Thus, the explanation for reduced
I toxicity for COX-2–specific inhibitors may be their lack
f dual COX inhibition rather than their COX-1–sparing
ffects.
In this framework, taking both a cardioprotective dose of
SA (primarily a COX-1 inhibitor at low dose [i.e., 325 mg
r less]) and a COX-2 inhibitor creates the ulcer risk of a
raditional NSAID. A high percentage of individuals re-
uiring cardioprotective doses of ASA have chronic pain
nd receive a traditional NSAID or a COX-2–selective
SAID (coxib). A survey that queried chronic coxib users
ound that 50% or more users were also taking ASA (15).
oreover, because coxibs were heralded as having an
mproved safety profile, related primarily to a lower rate of
I toxicity than traditional NSAIDs, the potential loss of
his safety advantage when a COX-2 inhibitor is combined
ith ASA or an OTC NSAID remains underappreciated by
linicians. Heightened attention to the cardiovascular risks
f NSAIDs has likely further increased the rate of addition
f ASA to anti-inflammatory therapy (16).
echanisms of
astroduodenal Injury—Clopidogrel
latelet aggregation plays a critical role in healing through
he release of various platelet-derived growth factors that
romote angiogenesis. Angiogenesis, in turn, is critical for
he repair of GI mucosal disruptions. Experimental animals
ith thrombocytopenia have been shown to have reduced
lcer angiogenesis and impaired ulcer healing (17). Addi-
ionally, adenosine diphosphate-receptor antagonists impair
he healing of gastric ulcers by inhibiting platelet release of
ro-angiogenic growth factors, such as vascular endothelial
rowth factor, which promotes endothelial proliferation and
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oxic effect of chemotherapeutic agents that use monoclonal
ntibodies directed at circulating vascular endothelial
rowth factor (18). Although clopidogrel and other agents
hat impair angiogenesis may not be a primary cause of
astroduodenal ulcers, their anti-angiogenic effects may
mpair healing of gastric erosions or small ulcerations that
evelop because of other medications or Helicobacter pylori
nfection. This may then, in the presence of acid, lead to
linically significant ulceration and related complications.
. GI Complications of ASA and Non-ASA NSAIDs
ecommendation: As the use of any NSAID, including
OX-2–selective agents and OTC doses of traditional
SAIDs, in conjunction with cardiac-dose ASA, sub-
tantially increases the risk of ulcer complications, a
astroprotective therapy should be prescribed for at-risk
atients.
Upper gastrointestinal events (UGIE), symptomatic or
omplicated ulcers, occur in 1 of every 20 NSAID users and
n 1 of 7 older adults using NSAIDs (19), accounting for
0% of UGIE-related hospitalizations and deaths (20–22).
yspepsia, defined as upper abdominal pain or discomfort,
ay occur in individuals taking NSAIDs, including ASA.
yspepsia is not clearly predictive of the presence of an
lcer, as it is far more prevalent. Some patients may also
xperience an increase in symptoms of gastroesophageal
eflux disease on NSAIDs as well (23). Endoscopic ulcers
re used as a surrogate marker in clinical trials for risk of
edications and in treatment trials; this document focuses
n patients with dyspepsia and an ulcer (symptomatic ulcer)
r those with serious (life threatening) ulcer complications
uch as bleeding or perforation. The annual incidence of
SAID-related UGIE is 2.0% to 4.5% (19), and the risk of
leeding, perforation, or obstruction is 0.2% to 1.9%
19,24). NSAIDs contribute to 10–20/1000 hospitaliza-
ions per year and are associated with a 4-fold increase in
ortality (20). In the United States alone, NSAID use has
een extrapolated to account for approximately 107 000
ospitalizations and 16 500 deaths per year among patients
ith arthritis (25). More recent information regarding these
stimates related to NSAIDs suggests that these numbers
ay be too high, but increasing use of antiplatelet medica-
ions may contribute to an increased burden of GI bleeding
26–28). According to these reports, GI hospitalization
ates markedly declined (from 1.5% to 0.5%) between 1992
nd 2000. Four potential explanations were given: use of
ower doses of NSAIDS, less use of “more toxic” NSAIDs,
ncreased use of “safer” NSAIDs, and increased use of
roton pump inhibitors (PPIs).
Among elderly veterans, NSAID exposure has been
hown to increase risk of UGIE-related mortality 3-fold,
ven after adjustment for advancing age, comorbidity, and
roportion of time spent on a traditional or COX-2–
elective NSAID (26). In fact, if deaths resulting from
SAID-associated upper GI complications were tabulated Teparately, it would represent the 15th most common cause
f death in the United States (29). National data from the
epartment of Veterans Affairs reveal that 43.0% of the
eterans prescribed NSAIDs are considered to be at high
isk for UGIE and that patients 65 years or older constitute
he largest high-risk subset (87.1%) (8). Among elderly veter-
ns, the risk of NSAID-related UGIE has been estimated as
753 UGIE in 220 662 person-years of follow-up (30).
Those who combine an NSAID with ASA represent
nother high-risk group. When patients combine an
SAID with ASA, the annual risk of UGIE is 5.6%, with
oxibs providing no additional gastroprotection (7.5%
GIE/year). A number of observational studies have noted
2- to 4-fold increased risk of UGIE associated with the
oncomitant prescription of NSAIDs with low-dose ASA.
ata from Scandinavia indicated an annual incidence of
ospital admission for UGIE of 1.4% related to use of
SAIDs plus low-dose ASA versus 0.6% for low-dose
SA. Estimates of the relative risk (RR) of UGIE for
SAID plus ASA range from 3.8 (95% confidence interval
CI]: 1.8 to 7.8) (14) to 5.6 (95% CI: 4.4 to 7.0) when
ompared with ASA alone (30).
Endoscopic trials suggest that the GI toxicity of a coxib
lus ASA is additive, resulting in an overall risk of endo-
copic ulcer formation that parallels that seen with a
onselective NSAID (25,31). Additionally, evidence from
bservational studies and randomized controlled trials
RCTs) reveals that the risk of an NSAID plus ASA
xceeds that of a coxib plus ASA, although both were
arkedly increased by ASA (9,27,29). In this context,
hether one chooses a nonselective NSAID or a selective
OX-2 inhibitor has a minimal, and perhaps clinically
nsignificant, impact on the likelihood of serious adverse GI
utcomes. Thus, the selection of anti-inflammatory drug
herapy in such patients must involve consideration of
verall GI and cardiovascular risk of NSAIDs (32). The
ngoing PRECISION (Prospective Randomized Evalua-
ion of Celecoxib Integrated Safety vs Ibuprofen or
aproxen; NCT00346216) study, which is randomizing
rthritis patients with or at risk of cardiovascular disease to
buprofen, naproxen, or celecoxib, should provide more data
o help clarify these issues.
. GI Effects of ASA
ecommendation: The use of low-dose ASA for cardio-
rophylaxis is associated with a 2- to 4-fold increase in
GIE risk. Enteric-coated or buffered preparations do
ot reduce the risk of bleeding. For patients at risk of
dverse events, gastroprotection should be prescribed.
he risk of UGIE increases with ASA dose escalation;
hus, for the chronic phase of therapy, doses greater than
1 mg should not be routinely prescribed.
The AHA recommends low-dose ASA use among pa-
ients with a 10-year cardiovascular risk that is greater than
r equal to 10% (33,34), and the U.S. Preventive Services
ask Force recommends ASA cardioprophylaxis for pa-
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t has been estimated that 50 million Americans use
ow-dose ASA (i.e., 325 mg/day or less) regularly for
ardioprophylaxis (36). The use of low-dose ASA is asso-
iated with a 2- to 4-fold increased risk of UGIE (37,38),
hich is not reduced by the use of buffered or enteric-coated
reparations (39,40). Fourteen randomized placebo-
ontrolled trials have presented data on UGIE with cardiac-
ose ASA (75 to 325 mg per day) in adults. When these
ata are pooled, the absolute increased risk per year of
GIE with ASA is 0.12% when compared with placebo
number needed to harm833), with conflicting evidence
f risk reduction with lower doses (75 to 162.5 mg) versus
igher doses (greater than 162.5 to 325 mg) (41).
The estimated average excess risk of UGIE related to
ardioprophylactic doses of ASA is 5 cases per 1000 ASA
sers per year (42). Among elderly patients, the odds ratios
ORs) of bleeding with daily doses of ASA of 75, 150, and
00 mg are 2.3, 3.2, and 3.9, respectively (37). Dose
eduction does not appear to reduce antithrombotic bene-
ts; however, dose escalation does seem to increase bleeding
omplications (43). Additionally, case series implicate OTC
se of low-dose ASA in over one-third of the patients
dmitted for GI hemorrhage (44), suggesting that patients
ho self-medicate may be unaware of the significant in-
rease in their risk of UGIE.
The complexities of confirming a significant difference
cross the range of the low doses of ASA used for cardio-
rotection are discussed below. Meta-analyses have been
ontradictory in demonstrating a significant difference in
he risk of GI bleeding (45,46). Observational studies are
omewhat contradictory, supporting evidence of a trend for
n association between higher ASA dose and risk of upper
I complications (37,47). The ACC and AHA recommend
owering the dose from 325 to 81 mg among those with a
igh risk of UGIE (2). However, some experts feel it may be
rudent to use up to 325 mg a day of ASA for 1 month after
stent procedure, although it is not clear from the data
hether this dose is really necessary (2). While this low-
ose ASA approach makes sense intuitively because of the
ack of demonstrated additional cardiovascular benefits at
he higher dose (with certain limited exceptions, such as
cute coronary syndrome [ACS]), coupled with a likelihood
f increased risk of GI harm at the higher dose, the key
oint is that the benefit, in terms of GI bleeding risk
eduction with the lower dose, remains insufficient to
rotect high-risk patients and mandates the addition of
ther GI bleeding risk-reduction approaches. However, it is
nknown what the optimal dose of ASA really is. The
ntithrombotic Trialists’ Collaboration meta-analysis pro-
ides indirect evidence that higher doses of ASA are not
ore effective, at least at a population level (48). There are
bservational data from the CURE (Clopidogrel in unstable
ngina to prevent recurrent events) trial that suggest no
enefit from higher doses of ASA but a greater risk of
leeding (49). The CURRENT/OASIS-7 (Clopidogrel uptimal Loading Dose Usage to Reduce Recurrent
veNTs/Optimal Antiplatelet Strategy for InterventionS-7;
CT00335452) trial is randomizing ACS patients to
igher (300 to 325 mg) or lower (75 to 100 mg) ASA doses
n the range used for cardiovascular disease and may help to
larify this issue once the results are known.
The use of enteric-coated or buffered formulations does
ot appear to reduce the risk of GI bleeding complications
39,40,50), a finding that suggests that the upper GI
ide-effects of ASA are a result of a systemic effect, in
ddition to its potent topical action to induce chemical
njury. Anecdotal reports of reduced dyspepsia with these
roducts likely contribute to their uptake in practice (51).
While the risk factors for NSAID-related UGIEs have
een well characterized, there are much less data on the risk
f antiplatelet therapy. The synergism between ASA and
SAIDs was reviewed in detail in the previous section. A
istory of peptic ulcer, particularly with associated bleeding,
ppears to be the most important risk factor. Age is an
mportant risk factor as well, with the relative increase
eginning at age 60 years and rising in a nonlinear fashion
ith age. Gender is a less important concern, although the
isk of men is slightly higher than that of women (42). The
isk associated with combination antiplatelet and anticoag-
lant therapies is substantial as well, and each is discussed
elow given their importance in cardiology clinical practice.
. GI Effects of Combined ASA and
nticoagulant Therapy
ecommendation: The combination of ASA and antico-
gulant therapy (including unfractionated heparin, low-
olecular-weight heparin, and warfarin) is associated
ith a clinically meaningful and significantly increased
isk of major extracranial bleeding events, a large pro-
ortion from the upper GI tract. This combination
hould be used with established vascular, arrhythmic, or
alvular indication; patients should receive concomitant
PIs as well. When warfarin is added to ASA plus
lopidogrel, an international normalized ratio (INR) of
.0 to 2.5 is recommended (52).
The use of antiplatelet drugs for the initial management
f ACS is common and known to be effective (1,2). In some
linical settings, such as the initial and long-term manage-
ent of ACS, the combination of anticoagulant and anti-
latelet therapy is superior to antiplatelet therapy alone (53)
ut is associated with a substantial increase in UGIE, as
hown in observational studies (54–56) and multiple RCTs.
A meta-analysis of 4 RCTs of unfractionated heparin
lus ASA versus ASA alone for ACS demonstrated a 50%
ncrease in major bleeds (57), representing an excess of 3
ajor bleeds per 1000 patients. Low-molecular-weight
eparin given in conjunction with ASA also increases major
leeding, as demonstrated in the FRISC-1 (Fragmin during
nstability in Coronary Artery Disease-1) study (58) and
REATE (Clinical Trial of Reviparin and Metabolic Mod-
lation in Acute Myocardial Infarction Treatment Evalua-
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October 28, 2008:1502–17 ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Riskion) (59). A comprehensive meta-analysis of over 25 307
atients demonstrated that the benefits of adding warfarin
o ASA in the treatment of ACS must be weighed against
2-fold increased risk in major extracranial bleeding (OR
.4; 95% CI: 1.4 to 4.1), suggesting that as few as 67
dditional patients would need to be treated with ASA plus
arfarin to result in 1 additional major extracranial bleeding
vent (60).
Conditions such as venous thromboembolism or me-
hanical heart valves may necessitate long-term anticoagu-
ation. With certain mechanical heart valves, an INR target
f 2.0 to 2.5 may not be appropriate, and a higher INR may
e required. Depending on the patient’s specific bleeding
nd thrombotic risks, consideration may be given to stop-
ing the antiplatelet agent, as warfarin also has cardiopro-
ective effects (61).
. GI Effects of Clopidogrel
ecommendation: Substitution of clopidogrel for ASA is
ot a recommended strategy to reduce the risk of recur-
ent ulcer bleeding in high-risk patients and is inferior to
he combination of ASA plus PPI.
Because of their alternative molecular targets and inhibi-
ion of platelet activation, thienopyridines (i.e., clopidogrel,
iclopidine) taken on their own, or in combination with
SA, have been compared with ASA. The ACC/AHA
ractice guidelines recommend the use of clopidogrel for
ospitalized patients with ACS who are unable to take ASA
ecause of major GI intolerance (Class I, Level of Evidence:
recommendation) (2). This recommendation was largely
ased on the safety data of the CAPRIE (Clopidogrel
ersus Aspirin in Patients at Risk of Ischaemic Events)
tudy (62). This study compared clopidogrel 75 mg daily
ith a relatively high cardioprotective dose of ASA (325 mg
aily) for the prevention of ischemic events, including
yocardial infarction, stroke, and peripheral arterial disease.
fter a median follow-up of 1.91 years, the incidence rate of
ajor GI bleeding was lower in the clopidogrel group
0.52%) when compared with the ASA group (0.72%; p less
han 0.05). The rate of hospitalization for GI bleeding was
.7% with clopidogrel versus 1.1% with ASA (p0.012)
63). Although the risk of GI bleeding with clopidogrel was
ower than that with ASA, the difference was small (0.2%).
lopidogrel with ASA for at least 1 month is also recom-
ended for patients with a recent non–ST-segment
levation-ACS, with a preference of 12 months if the
leeding risk is not high (2,64). In patients who have
eceived drug-eluting stents, at least 12 months of uninter-
upted dual antiplatelet therapy is recommended (65). Data
rom the CURE (66), MATCH (Management of Athero-
hrombosis with Clopidogrel in High-Risk Patients) (67),
nd CHARISMA (Clopidogrel for High Atherothrom-
otic Risk and Ischemic Stabilization, Management, and
voidance) studies (68) provide confirmatory evidence that
ombined ASA and clopidogrel therapy is associated with
ignificantly increased risk of UGIE complications when aompared with either agent alone (69). In patients at high
isk of bleeding who require a stent, a bare-metal stent, with
ts shorter requisite duration of dual antiplatelet therapy,
ay be preferable (4,70).
Concomitant use of clopidogrel and an NSAID (includ-
ng low-dose ASA) has been associated with impaired
ealing of asymptomatic ulcers (17) and disruption of
latelet aggregation (71), with a consequent increase in
erious UGIE (OR 7.4; 95% CI: 3.5 to 15) (28). Few
uman studies document clopidogrel’s potential for inde-
endent injury to the GI mucosa. A single endoscopic study
ith limited follow-up failed to demonstrate mucosal injury
n humans (72). In a hospital-based, case-control study of
777 consecutive patients with major upper GI bleeding and
532 controls, it was found that non-ASA antiplatelet drugs
clopidogrel, ticlopidine) had a similar risk of upper GI
leeding (adjusted RR 2.8; 95% CI 1.9 to 4.2) to ASA, at a
ose of 100 mg/day (adjusted RR 2.7; 95% CI: 2.0 to 3.6), or
nticoagulants (adjusted RR 2.8; 95% CI: 2.1 to 3.7) (73).
A prospective, double-blind RCT comparing ASA plus
someprazole against clopidogrel among H. pylori–negative
atients with recent UGIE secondary to low-dose ASA
emonstrated a significantly higher proportion of recurrent
GIE in the clopidogrel arm versus the ASA plus esome-
razole (20 mg twice daily) arm during the 12 months of
tudy (8.6% versus 0.7%; 95% CI on the difference: 3.4% to
2.4%) (74). A subsequent randomized trial with very
imilar design has shown virtually identical results (13.6%
GIE in the clopidogrel group versus 0% in the ASA plus
someprazole group [20 mg daily]; 95% CI on the differ-
nce: 6.3% to 20.9%) (75). These data suggest that use of
lopidogrel alone to reduce GI bleeding as an alternative to
SA is not a safe strategy and support ASA cotherapy with
nce-daily PPI. It remains unclear whether clopidogrel
xerts an independent injurious effect on the GI mucosa, or
hether it merely induces bleeding in already damaged
ucosa via its antiplatelet effects. Observational studies have
uggested that PPI cotherapy is beneficial to reduce the risk
f clopidogrel monotherapy as well (76).
. GI Effects of Combined Clopidogrel and
nticoagulant Therapy
ecommendation: The combination of clopidogrel and
arfarin therapy is associated with an increased incidence
f major bleeding when compared with monotherapy
lone. Use of combination antiplatelet and anticoagulant
herapy should be considered only in cases in which the
enefits are likely to outweigh the risks. When warfarin
s added to ASA plus clopidogrel, an INR of 2.0 to 2.5 is
ecommended (52).
A paucity of evidence informs the clinical risk of combi-
ation therapy with clopidogrel or ticlopidine. Anticoagu-
ant agents are not by themselves ulcerogenic; however, they
re associated with an increased risk of UGIE because of an
xacerbation of pre-existing lesions in the GI tract associ-
ted with NSAIDs, ASA, or H. pylori infection (76).
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ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Risk October 28, 2008:1502–17linically, this combination of ASA plus clopidogrel or
iclopidine together with anticoagulation, while not rou-
inely recommended, is sometimes utilized among patients
ith atrial fibrillation, peripheral arterial disease, and coro-
ary artery disease with percutaneous coronary intervention.
ith certain mechanical heart valves, an INR target of 2.0
o 2.5 may be too low (61), and a patient’s individual
hrombotic and bleeding risks need to be assessed.
The WAVE (Warfarin and Vascular Evaluation) study
andomized 2161 patients with peripheral arterial disease to
eceive warfarin plus antiplatelet therapy (ASA or thienopy-
idine) or warfarin monotherapy. No substantial difference
as noted in the composite cardiovascular outcome of
yocardial infarction, stroke, or death; however, more
leeding events requiring significant transfusion or surgical
ntervention were noted among patients receiving combina-
ion therapy (RR 3.4; 95% CI: 1.8 to 6.4) (53), despite the
act that few participants had an INR in excess of 3.0 (77).
nfortunately, the number of patients prescribed ticlopidine
r clopidogrel in combination with an anticoagulant in the
AVE trial was very small (6%); thus, the magnitude of
isk of combined anticoagulant-thienopyridine therapy re-
ains unclear. However, despite a priori exclusion of
atients on NSAIDs and with prior history of UGIE, nearly
0% of patients terminated anticoagulation therapy because
f bleeding episodes; no comment was made on the number
igure 1. Steps for Minimizing Gastrointestinal BleedingPI therapy is believed to reduce the risk in all patients; the more risk factors present, the
ee text for additional considerations. GI indicates gastrointestinal; GERD, gastroesophagef major bleeding events that originated from the GI tract.
n a recent article describing bleeding risk in patients
eceiving triple therapy with ASA, clopidogrel, and antico-
gulation, the incidence of both major and minor bleeding
as substantially increased (78). Such combination therapy
hould be maintained only in patients in whom the benefit
n cardiovascular protection outweighs these significant risks
nd a combination therapy with chronic PPI use seems
rudent.
. Treatment and Prevention of ASA- and
SAID-Related Gastroduodenal Injury
ecommendation: PPIs are the preferred agents for the
herapy and prophylaxis of NSAID- and ASA-associated
I injury.
The selection of patients for therapy to reduce the risk of
ntiplatelet therapy should consider the risk factors dis-
ussed in the preceding section, as well as concurrent
edical illness. A suggested approach is outlined in Figure
. Given the relative safety of cotherapy to reduce risk,
onsideration of risk factors mainly relates to the provision
f cost-effective care.
Prostaglandin depletion is the central mechanism for
SAID–ulcer development, and replacement therapy with
he synthetic prostaglandin, misoprostol, reduces NSAID
oxicity. Little data specifically address the impact of miso-more cost-effective the additional therapy likely becomes.
al reflux disease; and PPI, proton pump inhibitor.
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October 28, 2008:1502–17 ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Riskrostol on ASA-related injury, although one would expect,
iven the reduced ulcerogenic effects of low-dose ASA com-
ared with those of full-dose NSAIDs, that it would be
ffective for that purpose as well. In an endoscopic study,
isoprostol 100 mcg/day significantly reduced the develop-
ent of erosions in healthy volunteers taking ASA 300 mg/day
79). In addition, misoprostol has been shown to be superior to
lacebo for preventing recurrence of gastric ulcers among
atients with a history of gastric ulcer who were receiving
ow-dose ASA and another NSAID (80). However, misopros-
ol is associated with side effects, particularly diarrhea, that
ften lead to treatment discontinuation. For example, in a
tudy of more than 8000 rheumatoid arthritis patients, 20% of
atients receiving misoprostol withdrew within the first month
f treatment because of diarrhea (81). Although it is the only
.S. Food and Drug Administration–approved regimen for
he prevention of NSAID ulcers and complications, it is rarely
sed because of the prevalence of the side effects of diarrhea
nd abdominal cramping.
Sucralfate, a basic aluminum salt of sucrose octasulfate,
orms an ulcer-adherent complex at duodenal ulcer sites,
rotecting the ulcer and promoting healing; sucralfate may
lso inhibit pepsin activity in gastric fluid. Sucralfate has
een shown to be effective in the treatment of NSAID-
ssociated duodenal ulcers, particularly when the NSAID is
topped, but is not effective in the treatment or prevention of
SAID-related gastric ulcers. Its use is not recommended
ecause of the availability of far superior alternatives.
The level of acid suppression provided by traditional
oses of H2-receptor antagonists (H2RAs) does not prevent
ost NSAID-related gastric ulcers. There are little data on
heir use in conjunction with ASA. The H2RA ranitidine,
t a dose of 150 mg/day, significantly increased intragastric
H and reduced the amount of gastric bleeding in subjects
aking ASA 300 mg/day (82). Similar results were seen in 2
urther trials in volunteers (83). Despite a single endoscopic
tudy demonstrating that H2RAs at double the usual dose
ay be effective compared with placebo, studies comparing
igh doses of H2 blockers to misoprostol or PPIs for the
revention of NSAID ulcers are not available. Given com-
liance concerns with twice-daily dosing, PPI therapy is the
ational alternative to H2RAs in this clinical setting. PPIs
ave been proven superior to both ranitidine and misopros-
ol in preventing NSAID ulcer recurrence and overall
ymptom control, largely related to their ability to reduce
lcers and improve NSAID-associated dyspepsia, thereby
ffecting overall quality of life. No randomized controlled
ata are available from studies evaluating the impact of H2
lockers on low-dose ASA-related injury.
PPIs inhibit the parietal cell proton pump, thus exerting
suppressive effect on gastric acid. In endoscopic studies
nvolving healthy volunteers, both lansoprazole and ome-
razole significantly reduced the risk of gastroduodenal
esions in patients taking ASA 300 mg/day (51). These
esults were confirmed by epidemiological studies in which
oncomitant antisecretory therapy, especially PPI therapy, Eas associated with a significant RR reduction of upper GI
leeding among patients receiving low-dose ASA (76,84).
hese data in the literature do not demonstrate evidence
hat supports the need for greater than the standard once
aily dosing for PPI therapy as indicated in labeling for
lcer disease indications, despite the greater levels of acid
uppression afforded by more frequent or higher daily
osing. Maximal acid inhibitory effects of most PPIs are
chieved if food is consumed within 30 minutes of dosing;
his is most relevant for gastroesophageal reflux disease
ymptom control, but it is not known if this concern is
elevant for ulcer prevention therapy.
Lansoprazole 30 mg/day was compared with placebo for
ecurrence of ulcer complications in patients taking ASA
00 mg/day for 12 months after eradication of H. pylori and
ealing of ulcers. Patients in the lansoprazole group were
ignificantly less likely to have a recurrence of ulcer compli-
ations, suggesting that PPI therapy plus H. pylori eradica-
ion is superior to H. pylori eradication alone (85). Although
of 9 patients in the placebo group who rebled had either
ailed eradication or had H. pylori reinfection, this study
ndicates that antibiotic treatment alone provides insuffi-
ient protection for low-dose ASA users at high risk. Chan
t al. (86) reported that among patients with H. pylori
nfection and a history of upper GI bleeding, omeprazole
herapy was equivalent to eradication of H. pylori in pre-
enting recurrence of bleeding. However, the follow-up
ime in this study was relatively short (6 months). In an
bservational study, Lanas et al. (87) reported a low inci-
ence of upper GI complications among high-risk patients
eceiving low-dose ASA plus omeprazole.
As discussed elsewhere, the predominant antiplatelet
ffect of ASA promotes bleeding from established lesions
including H. pylori–induced ulcers) and creates new ulcers.
ased upon data on full-dose NSAID therapy, PPI therapy
s believed to tip the balance so that small lesions do not
rogress to larger lesions that can become symptomatic (88).
his is important, as observational studies with the occur-
ence of GI hemorrhage as their end point may document
hanges in the rate of ulcer bleeding but fail to assess the
revalence of ASA-related ulcers. This is very relevant to
he interpretation of case-controlled studies from areas of
igh H. pylori prevalence, which, indeed, provide much of
he data on this issue and which also suggest a possible role
or H2RA therapy. The administration of an H2RA, by
educing the burden of H. pylori–related ulcers, lessens the
ikelihood of GI bleeding events related to the antiplatelet
ffect of ASA therapy (76,84).
Combining a PPI with clopidogrel appears to result in
ess GI bleeding (76,89). To date, despite some in vitro data
o suggest an interaction due to metabolism by the cyto-
hrome P450 pathway, there has been relatively little
vidence of any clinically significant interaction between
lopidogrel and PPIs (90). The ongoing COGENT-1
Clopidogrel and the Optimization of Gastrointestinal
vents; NCT00557921) study is randomizing patients with
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ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Risk October 28, 2008:1502–17oronary artery disease to ASA plus clopidogrel in combi-
ation with omeprazole 20 mg or placebo and should
rovide further evidence to help address these issues.
. Role of H. pylori
ecommendation: Testing for and eradicating H. pylori
n patients with a history of ulcer disease is recommended
efore starting chronic antiplatelet therapy.
Unlike results of studies among non-ASA NSAID users,
ase-control studies have consistently shown that H. pylori is
n important risk factor for ulcer and ulcer bleeding in users
f low-dose ASA (38,91,92). In a case-control study of 695
onsecutive users of low-dose ASA with upper GI bleeding,
. pylori infection was identified as an independent risk
actor of upper GI bleeding (OR 4.7; 95% CI: 2.0 to 10.9).
ther risk factors identified were a previous ulcer history
OR 15.2; 95% CI: 3.8 to 60.1), alcohol use (OR 4.2; 95%
I: 1.7 to 10.4), and use of calcium-channel blockers (OR
.54; 95% CI: 1.25 to 5.14) (91).
Whether eradication of H. pylori infection in patients
ith a history of ulcer prior to starting ASA will reduce
ubsequent ulcer risk has been controversial. In a 6-month
andomized trial of H. pylori eradication versus maintenance
herapy with omeprazole in ASA users with H. pylori
nfection and a recent history of ulcer bleeding (n250),
ates of recurrent ulcer bleeding were comparable between
he 2 treatment groups (1.9% in the eradication therapy
roup and 0.9% in the omeprazole group; 95% CI for the
ifference: 1.9% to 3.9%) (86). In another randomized
rial, all ASA users with H. pylori infection and a history of
lcer bleeding received a course of eradication therapy. They
ere then randomly assigned to receive lansoprazole (n62)
r placebo (n61) for up to 12 months. It was found that
.6% (95% CI: 0% to 9%) of patients in the lansoprazole
roup compared with 14.8% (95% CI: 7% to 26%) in the
lacebo group had recurrent ulcer bleeding (85). In the
atter study, however, two-thirds of the patients with
ecurrent ulcer bleeding in the placebo group either had
ailure of H. pylori eradication or used concomitant
SAIDs. Thus, whether eradication of H. pylori alone
ould adequately reduce the risk of ulcer bleeding in ASA
sers with high GI risk is uncertain. Nevertheless, prophy-
axis with a PPI effectively prevents recurrent upper GI
leeding with low-dose ASA, despite failure of H. pylori
radication and concomitant use of non-ASA NSAIDs.
A more recent study, and the largest to date, has gone
ome way towards clarifying this issue. In this prospective
ohort study, the incidence rates of ulcer bleeding were
ompared among 3 different cohorts of low-dose ASA users,
amely, patients without prior ulcer history who just started
sing ASA (n548), ASA users with prior ulcer bleeding
nd H. pylori infection who had successful eradication of H.
ylori (n250), and H. pylori–negative ASA users who had
rior ulcer bleeding (n118). All patients received low-dose
SA (less than 160 mg daily) without a gastroprotectivegent. After a median follow-up of 48 months, the annu- dlized incidence rate of ulcer bleeding in the 3 groups was
.5%, 1.1%, and 4.6%, respectively (93). Thus, current
vidence suggests that confirmed eradication of H. pylori in
SA users with prior ulcer bleeding significantly and
ubstantially reduces the risk of recurrent bleeding. Whether
his strategy would be beneficial in emergent situations such
s ACS is unknown.
. Diagnosis of H. pylori
recently published ACG guideline provides a compre-
ensive source of information on H. pylori (94). Noninvasive
. pylori testing is currently recommended for patients who
o not need endoscopy. Two general categories of nonin-
asive tests are now available: tests that identify active
nfection and tests that detect antibodies (exposure). This
istinction is important because antibodies (i.e., positive
mmune response) indicate only the presence of H. pylori at
ome time. Antibody tests do not differentiate between
reviously eradicated and currently active H. pylori. Com-
ared with tests for active infection, tests for antibodies are
impler to administer, provide a faster result, and are less
xpensive. However, the probability that a positive antibody
est reflects active infection decreases as the proportion of
atients with previously eradicated H. pylori increases.
uccessfully treated patients include both patients given
ntibiotics specifically for H. pylori and patients with undi-
gnosed H. pylori who had their H. pylori eradicated by
ntibiotics given for another infection; less common is
pontaneous eradication of H. pylori infection.
H. pylori serologic tests that detect antibodies to H. pylori
ave a sensitivity and specificity of approximately 90%. In
opulations with low disease prevalence, the positive pre-
ictive value of the test falls dramatically, leading to unnec-
ssary treatment. Office-based serologic tests are less accurate
han laboratory-based enzyme-linked immunosorbent assay
ests but have the advantage of providing a result within 30
inutes. Serology tests should be used only for initial diagno-
is, because antibody levels often remain elevated after H. pylori
s eliminated. Serology tests should not be used to confirm a
ure after a patient has been treated for H. pylori.
. Tests for Active H. pylori
ests for active H. pylori include fecal H. pylori antigen
esting and urea breath testing (UBT). For the UBT, the
atient drinks an oral preparation containing 13C or 14C-
abeled urea. H. pylori bacteria in the stomach metabolize
his urea; the blood stream absorbs the carbon and it travels
o the lungs, which exhale it as carbon dioxide. The carbon
ioxide isotope is measured to determine the presence or
bsence of H. pylori. This test has a sensitivity and specificity
f more than 90% for active infection. A number of drugs
an adversely affect the accuracy of UBT. Prior to any form
f active testing, antibiotics and bismuth should be withheld
or at least 4 weeks, PPIs should be withheld for at least 7
ays, and patients should fast for at least 6 hours.
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October 28, 2008:1502–17 ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI RiskThe stool antigen test has been reported to have a
ensitivity and specificity of more than 90% in untreated
atients with suspected H. pylori infection. It requires
ollection of a stool sample the size of an acorn by either the
linician or the patient. This test must be performed in a
aboratory by trained personnel. Based upon available data,
t is reasonable to conclude that the fecal antigen test can be
sed interchangeably with the UBT to identify H. pylori
efore antibiotic therapy.
. Treatment of H. pylori
he choice of therapy should consider effectiveness and cost
f various regimens versus side effects. PPIs have in vitro
ctivity against H. pylori. A PPI plus clarithromycin (500
g) plus either amoxicillin (1 g) or metronidazole (500 mg)
iven twice daily has demonstrated eradication rates near
0% when used for 10 to 14 days. Amoxicillin is preferred
or patients who have been treated with metronidazole previ-
usly. Metronidazole is preferred for patients allergic to peni-
illin. “Bismuth-based triple therapy” is a less costly alternative:
bismuth subsalicylate) 2 tablets daily, metronidazole 250 mg
our times daily, and tetracycline 500 mg four times daily for 2
eeks is the best studied, highly effective anti–H. pylori therapy
greater than or equal to 85% eradication). The duration and
ultidrug nature of this regimen have been associated with
ecreased compliance, leading to potential failure to eradicate.
he complexity of testing and treatment ofH. pylori, despite its
pparent value as a sole therapy to reduce risk, supports the
uperiority of PPI therapy alone in its simplicity and efficacy,
ven for H. pylori–infected patients, as demonstrated by the
tudy by Lai et al. (85).
. Discontinuation of Antiplatelet Therapy
ecause of Bleeding
ecommendation: Decision for discontinuation of ASA
n the setting of acute ulcer bleeding must be made on an
ndividual basis, based upon cardiac risk and GI risk
ssessments to discern potential thrombotic and hemor-
hagic complications.
Patients receiving low-dose ASA who develop upper GI
leeding are often advised to discontinue ASA until ulcers
ave healed. A particular dilemma arises in patients requir-
ng continuous antiplatelet therapy (e.g., with ACS, acute
erebrovascular insufficiency, or recent percutaneous revas-
ularization) who develop actively bleeding ulcers. Can
SA be reintroduced immediately after endoscopic hemo-
tasis has been achieved, given that prolonged discontinua-
ion of ASA increases thrombotic risk in patients with
nstable cardiovascular diseases?
Hemodynamic instability and hemostatic changes in-
uced by acute bleeding may further increase the risk of
hrombosis in the absence of antiplatelet therapy. On the
ther hand, continuation of ASA in the setting of acute
lcer bleeding may provoke recurrent bleeding. There is no
vidence that non-ASA antiplatelet drugs such as clopi-
ogrel will reduce this bleeding risk in the presence of active tlcers (73). A meta-analysis of randomized trials showed
hat the intravenous administration of a PPI after endo-
copic therapy for bleeding ulcers reduced the risk of
ecurrent bleeding (OR 0.39; 95% CI: 0.18 to 0.87) and the
eed for surgery (OR 0.61; 95% CI: 0.40 to 0.93) (95).
owever, no previous trials permitted continuation of
ntiplatelet therapy during the study period. An in vitro
tudy suggested that hemostasis depends on pH and the
tability of the platelet plug (96). Antiplatelet drugs may
egate the hemostatic effect of a PPI by impairing platelet-
lug formation.
To date, only 1 small-scale, double-blind, randomized
rial evaluated the effect of early reintroduction of ASA in
atients with cardiovascular diseases who presented with
cute bleeding ulcers (97). By the time that an interim
nalysis was performed, 113 patients receiving ASA for
erebrovascular or cardiovascular diseases who developed
leeding gastroduodenal ulcers confirmed by endoscopy had
een enrolled. After endoscopic control of active bleeding,
hey were randomly assigned to receive ASA 80 mg once
aily or placebo. All patients received a continuous infusion
f a PPI for 72 hours and then a standard dose of an oral
PI for up to 8 weeks. The end points included recurrent
lcer bleeding within 30 days and all-cause mortality. The 2
roups were comparable in terms of age (mean age 74 years
ersus 73 years), gender (men: 62% versus 69%), prior ulcer
istory (6.9% versus 3.7%), concomitant use of NSAIDs
12% versus 11%), location (gastroduodenal ulcers: 28 versus
2), and diameter of ulcers (1.13 cm versus 1.20 cm).
ecurrent ulcer bleeding within 30 days occurred in 18.9%
f patients receiving ASA and 10.9% receiving placebo
p0.25). In the ASA group, 1 patient (1.7%) died of a
ecurrent cardiovascular event. In the placebo group, 8 patients
14.5%) died (5 recurrent cardiovascular events, 2 recurrent
leeding, and 1 pneumonia; p0.01 versus ASA group).
hese results suggested that the discontinuation of ASA was
ssociated with a significant increase in all-cause mortality,
ith most of the deaths being due to recurrent cardiovascular
vents. There was a numerical trend toward a higher rate of
ecurrent ulcer bleeding in the ASA group (18.9%), which
uggested that adjuvant PPI after endoscopic therapy could not
ffectively prevent early rebleeding induced by ASA.
. Endoscopy in Patients on Mono-
r Dual Antiplatelet Therapy
ecommendation: Endoscopic therapy may be per-
ormed in high-risk cardiovascular patients on dual
ntiplatelet therapy, and collaboration between the car-
iologist and endoscopist should balance the risks of
leeding with thrombosis with regard to the timing of
essation of antiplatelet therapy.
The American Society of Gastrointestinal Endoscopy
ractice guideline (98) on the use of antiplatelet and
nticoagulant medications in the setting of GI endoscopy
onsiders the risks and benefits of antiplatelet therapy with
he need for, and risks of, GI endoscopy with intervention.
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etting of multiple antiplatelet agents, it is quite clear that
ardiovascular concerns should remain paramount in the GI
ndoscopist’s practice; thus, cardiovascular risk weighs
eavily in clinical decision making. While many endosco-
ists would prefer to withhold dual antiplatelet agents in the
etting of an elective colonoscopy and polypectomy, the
ctual evidence that this practice reduces the risk of post-
olypectomy bleeding is marginal, at best (98). Therefore,
e encourage endoscopists to consider cardiovascular risks
nd to defer elective procedures in patients in whom a high
isk is present (e.g., those with recent placement of cardio-
ascular stents), for example, for a year after drug-eluting
tent placement. It is important to emphasize that the
uideline does not mandate discontinuation of ASA or
SAIDs for most endoscopic procedures because of a lack
f clear evidence that bleeding rates following an endoscopic
rocedure, such as a polypectomy, are adversely influenced.
The most likely setting where the issue of possibly
iscontinuing antiplatelet agents in a high-risk patient will
rise will be that of endoscopic therapy for GI bleeding.
his should be a rare occurrence, and again, individualized
isk stratification should be paramount. Based on the expert
onsensus of the writing committee, for those with chronic
lood loss and high cardiovascular risk, such as a recently
laced stent, dual antiplatelet therapy should be continued
s mandated by cardiovascular risk, given the lack of a
learly defined contraindication to endoscopic intervention.
In the acute setting following successful endoscopic and
edical treatment of major GI hemorrhage, it seems pru-
ent, following discussion among the specialties, to briefly
iscontinue antiplatelet therapy until lack of rebleeding is
bserved in the intensive care unit setting. The optimal
uration for cessation of antiplatelet therapy leading to a
alance of GI and cardiovascular outcomes has not been
stablished by clinical trials. The current efficacy of endo-
copic therapy for ulcer bleeding combined with intravenous
ontinuous-infusion PPI therapy suggests that reintroduc-
ion of antiplatelet therapy in such high-cardiovascular-risk
atients is reasonable in those who remain free of rebleeding
fter 3 to 7 days (97). In the far less common setting of
ndoscopic therapy for lower GI bleeding, even less avail-
ble data guide decision making. Since there is no adjunc-
ive medical therapy such as for ulcer bleeding with PPI,
ndoscopists may favor the use of nonthermal treatment
pproaches such as clipping and favor a delay of antiplatelet
herapy for 7 to 10 days, based upon lesion size and individu-
lized assessment of adequacy of endoscopic therapy.
ummary
n appropriate patients oral antiplatelet therapy decreases
schemic risks, but this therapy may increase bleeding
omplications. Of the major bleeding that occurs, the largest
roportion is due to GI hemorrhage. Concomitant use ofSAIDs further raises the risk of GI bleeding. Gastropro-
ection strategies consist of use of PPIs in patients at high
isk of GI bleeding and eradication of H. pylori in patients
ith a history of ulcers. Communication between cardiolo-
ists, gastroenterologists, and primary care physicians is
ritical to weigh the ischemic and bleeding risks in an
ndividual patient who needs antiplatelet therapy but who is
t risk for or develops significant GI bleeding.
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